J&J reports 73% PSA response for pasritamig + JNJ-9401 bispecific prostate combo

Johnson & Johnson says an investigational combination of two bispecific antibodies drove at least a 50% drop in PSA in 11 of 15 men with advanced prostate cancer, a 73% response rate, on dosing given once every six weeks ^[1].

The pairing links pasritamig and JNJ-9401, directed at the prostate antigens KLK2 and PSMA. J&J describes the regimen as a first-of-its-kind dual-antigen-targeted bispecific approach that uses complementary signals to activate T cells against the tumor ^[1]. The same 73% figure went out one day earlier, on 8 November 2026, through a company wire release ^[2].

Why it matters

Two things stand out for anyone running a prostate program. The combination hits two different prostate-restricted antigens at once rather than one, and J&J reports durable responses on an every-six-week schedule ^[1]. A T-cell engager that holds responses on so infrequent a cadence would be a competitive asset if the pattern survives a larger, controlled study.

Neither claim can be weighed yet. The disclosed result is a 15-patient PSA response rate with no comparator arm or survival data in the release ^[1]. PSA response is an early pharmacodynamic signal, not a clinical outcome, and 11 of 15 is a number that can move sharply as enrollment grows.

What Prognyx could not verify

The dataset sits entirely on J&J's own channels. No ClinicalTrials.gov registry record for the pasritamig plus JNJ-9401 trial appears in the set Prognyx reviewed, so the study's phase, enrollment target and endpoints could not be checked against a primary source. A secondary item from the aggregator Clinical Trial Vanguard described the population as metastatic rather than the advanced wording J&J uses; Prognyx could not read that page to resolve the difference ^[3].

What to watch next

No future catalyst date is public in these records. The disclosures that would turn this from a press signal into a verifiable readout are the trial's ClinicalTrials.gov registry record with its patient population and endpoints, a conference or peer-reviewed presentation reporting the same cohort with response durations, and any SEC filing in which J&J treats the program as material. None has appeared in the set Prognyx reviewed.

The now-what

For an operator with a competing prostate T-cell engager or a PSMA-directed asset, three moves are on the table. Treat this as a target-validation signal for KLK2 and PSMA as bispecific anchors, not as a dataset to reprice a program against. Hold any competitive reassessment until the trial's registry results or a conference dataset put an n and a response duration behind the 73%. And watch whether J&J itself elevates the program into an SEC filing or a medical meeting, which would signal the company's own read of how real the number is.

Threat level: low on the strength of today's evidence. The signal is credible but the cohort is small and the sourcing is single-party. Window: reassess when the trial's results or a peer-reviewed or conference dataset appear.